Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
WEBDec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F...
CDC Updates RSV Vaccination Recommendation for Adults
WEBJun 26, 2024 · Eligible adults can get an RSV vaccine at any time, but the best time to get vaccinated is in late summer and early fall before RSV usually starts to spread in communities. Today’s updated recommendation for people 60 and older replaces the recommendation made last year to simplify RSV vaccine decision-making for …
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the …
WEBMay 31, 2023 · INDICATION FOR ABRYSVO. ABRYSVO is a vaccine indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in people 60 years of age and older. IMPORTANT SAFETY INFORMATION FOR ABRYSVO.
The new RSV vaccines for older adults - Mayo Clinic Press
WEBSep 19, 2023 · Both vaccines are currently available. Here’s what you need to know about RSV and the two new vaccines designed to protect against it. What is RSV? Respiratory syncytial virus, commonly referred to as just “RSV,” is an RNA virus that can cause cold-like symptoms and lung and respiratory tract infections. RSV has an A …
FDA approves Moderna’s mRNA RSV vaccine for older adults
WEBMay 31, 2024 · The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
WEBMay 31, 2024 · mRESVIA ® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · Moderna is finishing its Phase 3 trial of an mRNA vaccine for RSV in older adults and expects to submit the results to the FDA for approval within the next few months.
ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine ...
WEBSep 5, 2024 · On May 31, 2024, the Food and Drug Administration (FDA) approved Moderna mRNA-1345 (mResvia) for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged ≥60 years. 1 mResvia is an unadjuvanted mRNA-based vaccine that consists of lipid nanoparticles (LNPs) that encapsulate linear mRNA ...
FDA approves mRNA-based RSV vaccine - Nature
WEBJun 7, 2024 · The FDA has approved Moderna’s mRNA-based respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) to protect adults aged 60 years and older from lower respiratory tract disease....
mRNA vaccine effective against RSV respiratory disease - Nature
WEBFeb 15, 2023 · Moderna has announced topline results for its mRNA-based vaccine against respiratory syncytial virus (RSV) infection in adults 60 years of age and older. mRNA-1345 targets the RSV...